What I’d do after the Futura Medical share price rose 65% today 

The Futura Medical share price has made impressive advances following regulatory progress. But will its stock price continue to rally?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Pharmaceutical stock Futura Medical (LSE: FUM) has risen 65% today as I write. This follows quick regulatory progress for its treatment in the past few days. 

This sounds promising. However, I do think it is important to figure out if the news is as good as it sounds on the surface. And following from there, if the company can sustain its share price increase. 

Regulatory progress 

The impetus for the share price increase was an agreement between the US Food and Drug Administration and Futura Medical. A clinical study of its erectile dysfunction treatment (MED3000) has to now be conducted. This is one step forward for the company in obtaining regulatory approval from the country.

This release follows a recommendation for approval by an EU body last week. This would allow MED3000 to be sold over-the-counter in the region. An EU approval will allow fast-track reviews in countries in the Middle East, Africa and Latin America. It could then become quickly available in these countries too. 

Capturing market share

Futura Medical’s treatment targets a treatment with growing demand. It is estimated that the erectile dysfunction drugs market will grow at a compounded annual rate of 5% between 2019 and 2026

I think this suggests that MED3000 could capture some of the market share of the growing segment, especially as Pfizer’s Viagra patent ended in 2020. This gives more pharmaceutical companies an opportunity to bring in their own version of erectile dysfunction treatments. 

At the same time, it also means more competition. In other words, MED3000 may or may not succeed, like any other Viagra substitute that is entering the market. 

Cannabis-based treatments

But Futura Medical has other treatments in the pipeline too. One of these is TPR100, an anti-inflammatory gel. It has conducted clinical studies and is currently awaiting regulatory authorisation in the UK. 

Interestingly, it is also developing cannabis-based treatments. Medical cannabis companies have recently started listing on the London Stock Exchange to much investor interest. In a joint venture with CBDerma Technology, the AIM-listed company will bring in its patented technology, DermaSys, for CBD treatment delivery through skin. 

No revenues

Futura Medical’s products and technology sound promising, but I think it is important to keep in mind that its revenues have been erratic over time. In the last two full years for which financial information is available – 2018 and 2019 – the company reported little by way of revenue. 

While things can change in the future, it does indicate that we do not know how they will turn out. Besides, it is loss-making too, as would be expected. 

What I’d do now

I think the stock has potential but it is also high risk, especially after the sudden and sharp rise in its share price. I reckon it will come off from here so I would not like to consider buying it now. As and when it gets the approvals for distribution for MED3000, I will take a look at the Futura Medical share again. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

The National Grid share price nosedived 21% in 2 days! Is it time to take advantage?

The National Grid share price tumbled after the company surprised shareholders by revealing plans to raise more money via a…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Dividend Shares

How I’d try to ironclad my second income before interest rates fall

Jon Smith explains a couple of tactics he's looking to implement in his dividend portfolio to try and protect his…

Read more »

Investing Articles

The FTSE 100 still looks cheap to me. But don’t just take my word for it!

The FTSE 100 (INDEXFTSE:UKX) has increased 7.5% since the start of 2024. But I think there’s evidence to suggest that…

Read more »

Investing Articles

What should the Vodafone share price be? Here are 3 possible answers

Our writer uses a number of popular financial measures to come up with an estimate of a fair value for…

Read more »

Investing Articles

Here’s how much I’d have if I’d bought 1,000 shares in this FTSE 100 defence stock 5 years ago

I could have made a pretty penny investing in this leading FTSE 100 defence stock. Now I’m looking at a…

Read more »

Investing Articles

1 potential millionaire-maker UK stock I’d like to buy for the long haul

For long-term investors, here’s 1 UK stock to consider buying right now with the potential to help power a growth…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

These cheap UK shares look way too good to ignore right now

With the UK stock market reaching new highs recently, this Fool plans to grab these two remaining cheap shares before…

Read more »

Young Woman Drives Car With Dog in Back Seat
Investing Articles

This unloved UK stock could rise 120%, according to a City broker

Some City analysts reckon a once-popular UK stock can recover from its massive recent decline and go on to more…

Read more »